Maxim Group Upgrades bluebird bio (BLUE) to Buy Ahead of ASCO Presentation
Tweet Send to a Friend
Maxim Group upgraded bluebird bio (NASDAQ: BLUE) from Hold to Buy with a price target of $100.00.Analyst Jason McCarthy believes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
